Показано 0 из 0
Дата |
---|
10:31 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
20.25
|
20.93
|
20.28
|
20.25
|
20.28
|
20.25
|
|
|
|
|
20.45
|
20.69
|
20.34
|
20.32
|
20.47
|
20.47
|
|
|
|
|
20.68
|
20.93
|
20.62
|
20.56
|
20.79
|
20.65
|
|
|
|
|
20.83
|
21.08
|
20.79
|
20.79
|
20.90
|
20.90
|
|
|
|
|
20.92
|
21.17
|
20.54
|
20.54
|
20.89
|
20.89
|
|
|
|
|
20.84
|
21.09
|
20.49
|
20.34
|
20.65
|
20.65
|
|
|
|
|
20.66
|
20.91
|
20.48
|
20.46
|
20.62
|
20.54
|
|
|
|
|
20.71
|
20.96
|
20.42
|
20.35
|
20.76
|
20.76
|
|
|
|
|
20.55
|
20.79
|
19.985
|
19.945
|
20.61
|
20.61
|
|
|
|
|
20.16
|
20.40
|
19.865
|
19.865
|
20.22
|
20.22
|
|
|
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.